|
注册号: Registration number: |
ChiCTR2500097007 |
|
最近更新日期: Date of Last Refreshed on: |
2025-02-11 09:36:30 |
|
注册时间: Date of Registration: |
2025-02-11 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
评价磷丙泊酚二钠用于气管切开虚弱患者再次手术时麻醉诱导的有效性和安全性 |
|
Public title: |
Efficacy and safety of fospropofol disodium for anesthesia induction in patients with tracheotomy weakness during reoperation |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
评价磷丙泊酚二钠用于气管切开虚弱患者再次手术时麻醉诱导的有效性和安全性 |
|
Scientific title: |
Efficacy and safety of fospropofol disodium for anesthesia induction in patients with tracheotomy weakness during reoperation |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
赵泽宇 |
研究负责人: |
赵泽宇 |
|
Applicant: |
Zhao Zeyu |
Study leader: |
Zhao Zeyu |
|
申请注册联系人电话: Applicant telephone: |
+86 180 1131 0198 |
研究负责人电话:
Study leader's |
+86 180 1131 0198 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
gyzhaozy@163.com |
研究负责人电子邮件: Study leader's E-mail: |
gyzhaozy@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
https://www.81kf.cn/ |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
https://www.81kf.cn/ |
|
申请注册联系人通讯地址: |
四川省成都市温江区永宁街道八一路81号 |
研究负责人通讯地址: |
四川省成都市温江区永宁街道八一路81号 |
|
Applicant address: |
No. 81 Bayi Road, Yongning Street, Wenjiang District, Chengdu City, Sichuan Province |
Study leader's address: |
No. 81 Bayi Road, Yongning Street, Wenjiang District, Chengdu City, Sichuan Province |
|
申请注册联系人邮政编码: Applicant postcode: |
611135 |
研究负责人邮政编码: Study leader's postcode: |
611135 |
|
申请人所在单位: |
四川省八一康复中心(四川省康复医院) |
||
|
Applicant's institution: |
Sichuan Bayi Rehabilitation Center (Sichuan rehabilitation hospital) |
||
|
研究负责人所在单位: |
四川省八一康复中心(四川省康复医院) |
||
|
Affiliation of the Leader: |
Sichuan Bayi Rehabilitation Center (Sichuan rehabilitation hospital) |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
CKLL-20241215 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川省八一康复中心(四川省康复医院)伦理委员会 |
||
|
Name of the ethic committee: |
The ethics committee of Sichuan Bayi Rehabilitation Center (Sichuan rehabilitation hospital) |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-12-26 00:00:00 | ||
|
伦理委员会联系人: |
林贞仿 |
||
|
Contact Name of the ethic committee: |
Lin Zhenfang |
||
|
伦理委员会联系地址: |
四川省成都市温江区永宁街道八一路81号 |
||
|
Contact Address of the ethic committee: |
No. 81 Bayi Road, Yongning Street, Wenjiang District, Chengdu City, Sichuan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 134 8890 8713 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
四川省八一康复中心(四川省康复医院) |
||||||||||||||||||||||
|
Primary sponsor: |
Sichuan Bayi Rehabilitation Center (Sichuan rehabilitation hospital) |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省成都市温江区永宁街道八一路81号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 81 Bayi Road, Yongning Street, Wenjiang District, Chengdu City, Sichuan Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
四川省医学会专项经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
Special Fund of Sichuan Medical Association |
||||||||||||||||||||||
|
研究疾病: |
气管切开再手术患者 |
||||||||||||||||||||||
|
Target disease: |
Tracheotomy reoperation patients |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
评价磷丙泊酚二钠用于气管切开虚弱患者再次手术时麻醉诱导的有效性和安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the efficacy and safety of fospropofol disodium for anesthesia induction in patients with tracheotomy weakness during reoperation. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
选择气管切开后再次手术的患者140 例,按随机数字表法分为2 组(n=70):试验组和对照组。静脉注射舒芬太尼5μg,试验组静脉注射磷丙泊酚二钠10 mg/kg,对照组静脉注射瑞马唑仑0.2mg/kg,间隔5~6min 待睫毛反射消失后拔除气管套管,更换一次性加强型气管导管。于诱导前(T0)、换管前即刻(T1)和换管后即刻(T2)记录MAP 及HR。记录注射部位疼痛、麻醉起效时间及换管时呛咳等不良反应的发生情况。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
140 patients with reoperation after tracheotomy were randomly divided into two groups (n=70): experimental group and control group. Sufentanil (5 μ g) was injected intravenously, disodium propofol (10 mg/kg) was injected intravenously in the experimental group, and remimazolam (0.2 mg/kg) was injected intravenously in the control group. After eyelash reflex disappeared, tracheal cannula was removed and disposable reinforced tracheal tube was replaced. Map and HR were recorded before induction (T0), immediately before tube replacement (T1) and immediately after tube replacement (T2). The incidence of adverse reactions such as pain at the injection site, onset time of anesthesia and cough during tube replacement were recorded. |
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1、有镇痛或镇静药物过敏史;2、近1 个月有使用苯二氮䓬类药物史;3、合并重症肌无力;4、未控制的3 级高血压病;5、发热或未控制的肺部感染。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Have a history of allergy to analgesic or sedative drugs; 2. have a history of using benzodiazepines in the past month; 3. have myasthenia gravis; 4. uncontrolled grade 3 hypertension; 5. have fever or uncontrolled pulmonary infection. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-02-17 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-02-17 00:00:00 至 To 2025-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
研究者采用计算机生成随机数字表 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The researcher uses computer to generate a random number table |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
项目完成6个月后,在医院管网公开原始数据。https://www.81kf.cn/ |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Six months after the completion of the project, the original data will be disclosed in the hospital pipe network. https://www.81kf.cn/ |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用excel表记录病例记录表(Case Record Form, CRF),采用医院HIS系统记录和收集数据。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Excel was used to record the case record form (CRF), and the hospital his system was used to record and collect data. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |